UroGen (URGN) - Bozor kapitallashuvining balans qiymatiga nisbati
UroGen Pharma Ltd. (URGN) uchun bozor tendentsiyasi hozirda -12.42 miqdorida baholangan aktiv dinamikasini aks ettiradi. Biznes buyrak neoplazmalarining invaziv bo'lmagan davolash imkonini beruvchi eksklyuziv RTGel texnologiyasiga tayanadi. Biroq, global mojarolar transchegaraviy klinik sinovlarga to'sqinlik qilmoqda va biomateriallar logistikasini buzmoqda. Shu bilan birga, ishlab chiqarish quvvatlari barqaror ishlamoqda, urologik mahsulotlar ishlab chiqarishda to'liq sterillikni saqlash uchun uskunalar doimiy ravishda yangilanmoqda.
%20Kapitallashuvning%20sof%20aktivlarga%20nisbati&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_URGN_-_UroGen-Pharma-Ltd._-_Market-Cap-to-Net-Assets-Ratio "UroGen (URGN) Bozor kapitallashuvining balans qiymatiga nisbati: 04.07.2022 - 29.10.2026 davri uchun | 👁️GURU.Markets👁️")
UroGen Pharma Ltd (URGN) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti
- bozor qiymati va tahlilchilarning maqsadli prognozi:
- bozor kapitallashuvi ko'rsatkichlari:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzdorlik va likvidlik to'g'risida ma'lumotlar:
Umumiy qarzning kapitalga nisbati UroGen Pharma Ltd.|URGN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati UroGen|URGN - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati UroGen|URGN - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli majburiyatlari UroGen Pharma|Tezkor likvidlik koeffitsiyenti urogen.com
- foyda va baholash multiplikatorlari ko'rsatkichlari:
Kompaniyaning har tomonlama tahlili:UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) uchun onkologik dori-darmonlar yetkazib berish logistika zanjirlarini samarali diversifikatsiya qilish operatsion barqarorlikni va moddiy aktivlarning saqlanishini ta'minlaydi. Ushbu P/B koeffitsiyenti grafigini tahlil qilish orqali investorlar kitob qiymatidan yuqori bo'lgan bozor qiymati premiumini baholashlari mumkin, bu esa ularga haddan tashqari qimmat baholangan kotirovkalarni aniqlash va joriy bozor sharoitida biznesning ichki qiymatiga nisbatan narxning xavfsizlik zaxirasini belgilash imkonini beradi.
UroGen Pharma Ltd. kimlar bilan raqobatlashadi
BeiGene Ltd (ONC) - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati HALO|RVMD (Revolution Medicines, Inc.) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International (AAPG)|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati Bicara Corp (BCAX)|Bozor qiymatining balans qiymatiga nisbati Personalis, Inc. PSNL|ERAS: Kapitallashuvning balans qiymatiga nisbati|Delcath Systems - Bozor kapitallashuvining balans qiymatiga nisbati|Y-mAbs Therapeutics Inc (YMAB) - Kapitallashuvning sof aktivlarga nisbati|AURA: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Candel Therapeutics, Inc. (CADL)|Bozor qiymatining balans qiymatiga nisbati Accuray Incorporated|SLS: Balans qiymatiga nisbatan bozor qiymati|Kapitallashuvning sof aktivlarga nisbati ACTU (Actuate Therapeutics)|CTOR (Citius Oncology Inc.) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati HURA (TuHURA Biosciences)|TARA - Kapitallashuvning sof aktivlarga nisbati|FATE: Kapitallashuvning sof aktivlarga nisbati|WHWK - Bozor kapitallashuvining balans qiymatiga nisbati|tscan.com (TCRX) - Bozor qiymatining balans qiymatiga nisbati|Champions Oncology, Inc. - Balans qiymatiga nisbatan bozor qiymati|XBIT (XBiotech Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti CEL-SCI Corp CVM|Kapitallashuvning sof aktivlarga nisbati OSTX (OS Therapies Incorporated)|Bozor kapitallashuvining balans qiymatiga nisbati Radiopharm Theranostics Ltd (RADX)|Bozor qiymatining balans qiymatiga nisbati Artiva Biotherapeutics ARTV|Balans qiymatiga nisbatan bozor qiymati ANL|VERU - Bozor qiymatining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Tempest Therapeutics Corp|XLO: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining xususiy kapitalga nisbati Renovaro RENB|MURA (Mural Oncology PLC) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Kairos Pharma Inc KAPA|Bozor qiymatining balans qiymatiga nisbati OnKure Therapeutics Inc (OKUR)|w2.cytomed.sg - Kapitallashuvning balans qiymatiga nisbati|Curis - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati APLM|THAR - Bozor qiymatining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi ADVB|GNPX: Bozor kapitallashuvining balans qiymatiga nisbati|Calidi Biotherapeutics, Inc. - Balans qiymatiga nisbatan bozor qiymati|SBFM (Sunshine Biopharma) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati Xenetic Bio|Bozor qiymatining balans qiymatiga nisbati Salarius Pharmaceuticals, Inc. (SLRX)|PPBT (Purple Biotech Ltd) - Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati American Oncology Network, Inc. AONC|BGNE - Kapitallashuvning sof aktivlarga nisbati|Checkpoint Therapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|ELEV - Bozor kapitallashuvining balans qiymatiga nisbati|ICAD (icadmed.com) - Kapitallashuvning sof aktivlarga nisbati|Ikena Oncology - Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati Notable Labs Inc.|Bozor qiymatining balans qiymatiga nisbati VIRX|Kapitallashuvning sof aktivlarga nisbati MOR (MorphoSys AG)|Bozor kapitallashuvining balans qiymatiga multiplikatori NAYA|Bozor kapitallashuvining balans qiymatiga nisbati AAPGV (Ascentage Pharma)